IPM Take
Healthcare is increasingly good at collecting the ingredients of cardiometabolic risk. The harder part is assembling them into one clinical picture.
That gap is visible in preliminary data from 97 US clinical sites participating in the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative. Three quarters reported screening for CKM-related conditions, and 73% systematically screened patient populations for individual risk factors. Yet only 28% were using the PREVENT cardiovascular risk equations, only 22% were applying CKM syndrome staging and just 22% routinely measured waist circumference.
The numbers matter because the 2026 US CKM guideline was built around precisely the opposite model of care. Obesity, diabetes, chronic kidney disease and cardiovascular disease are not supposed to be assessed as parallel diagnoses that happen to coexist. The guideline recommends staging patients across the CKM continuum, quantifying cardiovascular risk with PREVENT and using that combined information to decide how aggressively to intervene.
The problem is not that clinicians have stopped measuring blood pressure, glucose or cholesterol.
They are measuring them.
The problem is that conventional healthcare can collect every abnormality separately and still fail to recognise the patient as a single high-risk cardiometabolic system.
This survey is preliminary, self-reported and restricted to clinics that had already joined an AHA quality-improvement initiative, so it cannot be treated as a representative estimate of US practice. If anything, however, that selection makes the implementation gap worth watching. These were sites specifically entering a programme designed to improve CKM care.
The new cardiometabolic era will not be won by publishing another staging diagram.
It will depend on whether somebody actually uses it on Monday morning.
Executive Summary
Preliminary research to be presented at the American Heart Association’s Scientific Sessions 2026 examined implementation of cardiovascular-kidney-metabolic syndrome assessment across 97 US clinical sites participating in the AHA’s CKM Health Initiative.
The initiative is a national quality-improvement programme designed to encourage earlier recognition and coordinated management of cardiovascular, kidney and metabolic disease.
Most participating sites were outpatient facilities, with primary care making up the largest clinical setting. Safety-net and non-academic organisations represented a substantial proportion of participating centres.
Traditional screening was relatively common. 75% of sites reported screening for CKM-related clinical conditions, while 73% systematically screened patient populations for individual CKM risk factors.
Implementation of the newer integrated tools was substantially lower.
Only 28% of sites reported using the PREVENT equations to estimate cardiovascular risk, while 22% used formal CKM syndrome staging.
Only 22% routinely measured waist circumference, despite current CKM guidance recommending assessment of abdominal adiposity alongside BMI because BMI alone cannot fully characterise obesity-related cardiometabolic risk.
PREVENT is designed to estimate 10-year and 30-year cardiovascular risk in adults without established cardiovascular disease and incorporates contemporary cardiovascular, kidney and metabolic information.
The 2026 AHA/ACC/ADA/ASN CKM guideline recommends PREVENT risk estimation for appropriate people in CKM stages 0 through 3 and uses predicted cardiovascular risk to inform staging, testing and treatment decisions.
The study should be interpreted cautiously. It is a conference abstract and has not yet undergone full peer review. The participating clinics were selected for a CKM implementation initiative rather than sampled randomly from US healthcare, only 97 of approximately 150 participating sites had contributed data to the analysis, and implementation status was self-reported.
The results therefore cannot establish how frequently CKM staging or PREVENT is used across US healthcare as a whole.
They do, however, provide an early measure of the distance between publishing an integrated cardiometabolic framework and embedding it into routine practice.
Why it matters
- HTA bodies: The value of cardiovascular risk tools does not end with discrimination statistics and validation cohorts. If a staging framework or prediction model is meant to influence therapy, assessment increasingly needs to consider whether it can be implemented reliably within real clinical workflows, whether it changes treatment decisions and whether those changes improve patient outcomes. A mathematically superior risk tool that remains unused has little population value.
- Payers: Integrated CKM assessment could identify patients who would benefit from earlier treatment of obesity, diabetes, hypertension, dyslipidaemia or kidney disease, potentially moving spending upstream from complications to prevention. But expanding screening without creating pathways for treatment risks producing more diagnoses without better outcomes. Coverage policies will need to align identification, medication access, follow-up and multidisciplinary care rather than funding each component in isolation.
- Industry / innovation partners: CKM implementation creates opportunities for electronic-health-record integration, automated staging, clinical decision support and risk calculation. The useful product will not be another standalone calculator that clinicians must remember to open. The greater opportunity is making CKM staging and PREVENT computation nearly invisible within routine workflow while still preserving clinician oversight and transparent decision-making.
Cardiometabolic medicine has spent the past several years changing its vocabulary because the old clinical boundaries no longer describe what happens to patients particularly well.
A person with obesity may develop hypertension and type 2 diabetes, followed by chronic kidney disease and eventually heart failure or atherosclerotic cardiovascular disease. Those conditions may appear in different parts of the medical record and be treated by different specialists, but biologically they often belong to the same interconnected trajectory.
The concept of cardiovascular-kidney-metabolic syndrome was created to make that trajectory visible.
The first dedicated US clinical practice guideline for CKM syndrome, published in June 2026 by the American Heart Association and American College of Cardiology with the American Diabetes Association and American Society of Nephrology, went further by turning the concept into an operational framework.
Patients can be staged according to their position along the CKM continuum. Cardiovascular risk can be quantified with the PREVENT equations. Kidney function, obesity, glycaemia, blood pressure and lipid abnormalities can then be interpreted together rather than as independent problems competing for attention.
On paper, the logic is difficult to argue with.
Implementation is proving harder.
A preliminary survey from the American Heart Association’s CKM Health Initiative, due to be presented at Scientific Sessions 2026 in Chicago, provides an early look at how far participating clinics have moved from conventional risk-factor screening toward the new integrated model.
The survey included 97 clinical sites.
Most were outpatient facilities, and primary care was the most heavily represented setting. Forty-four percent identified as safety-net organisations, 39% were non-academic and 16% academic, creating a mix of healthcare environments rather than a survey confined to major tertiary centres.
The reassuring finding is that clinics were not ignoring cardiometabolic risk.
Three quarters reported screening for CKM-related conditions. Nearly as many, 73%, systematically screened their patient populations for individual CKM risk factors.
The less reassuring finding is what happened after those pieces were collected.
Only 28% reported using PREVENT to estimate cardiovascular risk.
Only 22% reported using CKM syndrome staging.
And despite abdominal adiposity being an important component of the CKM framework, only 22% routinely measured waist circumference.
The difference between those numbers captures the implementation problem unusually well.
Healthcare is already measuring many of the variables it needs.
It has not yet consistently reorganised those variables into the framework that the new guideline recommends.
That distinction matters because the purpose of CKM syndrome is not simply to rename familiar risk factors.
If CKM becomes another label attached to patients who already have obesity, hypertension and diabetes without changing what clinicians do, it adds terminology rather than clinical value.
The staging framework is meant to do something more consequential.
At one end is CKM stage 0, representing people without CKM risk factors. Early stages capture excess or dysfunctional adiposity and metabolic risk. More advanced stages incorporate metabolic disease, chronic kidney disease, high predicted cardiovascular risk, subclinical cardiovascular disease and eventually established clinical cardiovascular disease.
The point is to recognise progression before the final organ complication becomes the reason for treatment.
That requires more than ordering laboratory tests.
It requires synthesis.
Consider a patient with obesity, mildly elevated blood pressure, prediabetes and early kidney dysfunction.
Traditional care can produce four separate observations, perhaps recorded at four separate encounters, none individually dramatic enough to trigger a major escalation.
A CKM framework asks whether the combination places that patient on a trajectory where earlier intervention is warranted.
PREVENT is supposed to provide another part of that answer.
The equations were derived from contemporary data on more than 6.5 million US adults and estimate both 10-year and 30-year risk of cardiovascular disease. Unlike older cardiovascular prediction models, the system was designed during an era in which kidney and metabolic health have become increasingly central to cardiovascular prevention.
The 2026 CKM guideline gives PREVENT a substantial role.
For people without known cardiovascular disease in CKM stages 0 through 3, risk estimation can inform staging itself, decisions about testing for subclinical disease and the prioritisation of preventive pharmacotherapy.
That makes the finding that fewer than one third of participating sites were using PREVENT more than a technical detail.
If risk estimation is embedded in the treatment algorithm, low adoption can become a treatment implementation problem.
The same applies to waist circumference.
BMI remains widely used because it is simple, inexpensive and deeply embedded in clinical workflows.
It is also incomplete.
Two people with the same BMI can have very different distributions of body fat and different degrees of visceral adiposity, which is why the CKM guideline recommends using waist circumference alongside BMI to better characterise adiposity-related risk.
Yet only 22% of surveyed sites reported measuring it routinely.
There is an almost mundane explanation for that gap.
Healthcare systems are remarkably resistant to adding even simple steps to crowded workflows.
Waist circumference requires a tape measure, a standardised method, staff training and somewhere in the electronic record to document the result. PREVENT requires the necessary variables to be available and a risk calculation to appear at the right moment. CKM staging requires somebody, or ideally the electronic record itself, to assemble multiple conditions and measurements into a coherent category.
None of these tasks is technologically extraordinary.
Together they compete with hundreds of other things primary-care teams are expected to do during a short appointment.
This is why guideline implementation frequently fails somewhere between scientific publication and clinical workflow.
The evidence may be available.
The recommendation may be clear.
The health system still needs to decide who performs the task, when it happens, where the information appears and what action follows.
CKM adds another layer of complexity because it deliberately crosses specialty boundaries.
A patient may simultaneously need obesity management, kidney-protective therapy, glucose-lowering medication with cardiovascular benefit, blood-pressure treatment and lipid management.
The guideline therefore recommends interdisciplinary care for patients with overlapping cardiovascular, kidney and metabolic disease and emphasises the importance of a coordination point person.
That recommendation addresses a structural weakness in modern chronic-disease management.
Specialisation has made medicine extraordinarily capable of treating individual organ systems, but patients with CKM syndrome often require the opposite architecture: somebody has to see the whole system.
Without that ownership, cardiology may assume diabetes management belongs to endocrinology. Endocrinology may expect kidney monitoring to sit with nephrology. Nephrology may correctly focus on renal preservation while lipid management remains with primary care.
Every specialist can perform their part competently while the patient still experiences fragmented prevention.
That is why the low adoption of CKM staging is more important than the success or failure of one new clinical score.
Staging forces the healthcare system to ask where the patient sits across the entire cardiometabolic continuum.
The survey suggests that many participating sites have not yet made that transition routine.
The results should not be exaggerated.
These 97 clinics are not a nationally representative sample of US healthcare. They were participating in an AHA quality-improvement initiative and had been selected partly according to community CKM burden, structural and social factors, rural location and organisation type.
Their responses were self-reported and therefore vulnerable to recall error and misclassification.
Only 97 of approximately 150 sites in the initiative had provided data for the baseline analysis.
Most importantly, the findings come from a scientific-meeting abstract rather than a full peer-reviewed publication.
They should therefore be treated as an implementation signal rather than a definitive audit of American cardiometabolic care.
Yet the selection of the sites makes the signal interesting in another way.
These were not clinics randomly encountering CKM terminology for the first time. They had entered an initiative specifically designed to improve coordinated cardiovascular, kidney and metabolic care.
If adoption is incomplete in that environment, widespread implementation across routine healthcare is unlikely to happen automatically.
The timing also matters.
The survey was conducted between August 2025 and June 2026, while the first full CKM guideline was published in June 2026. Some of the data therefore predate the guideline itself.
Low use of the new tools should not be interpreted as clinicians ignoring a recommendation that did not yet formally exist for much of the survey period.
Instead, the survey provides something potentially more valuable: a baseline against which implementation after the guideline can be measured.
The American Heart Association’s CKM Health Initiative is designed for exactly that purpose.
The four-year programme plans to work across 15 US geographic markets, engage roughly 150 hospitals and care sites and reach more than 265,000 patients.
That creates an opportunity to study not only whether clinics adopt CKM staging and PREVENT, but whether adoption actually improves care.
That second question is essential.
Healthcare has no shortage of risk scores.
Adding another calculation to the electronic record is not a meaningful outcome if it does not change treatment, improve adherence, reduce clinical inertia or prevent cardiovascular and kidney events.
Implementation therefore has to be evaluated as rigorously as the underlying science.
Does automated CKM staging identify high-risk patients earlier?
Does PREVENT change prescribing decisions?
Does routine urine albumin testing uncover kidney disease that otherwise would have been missed?
Does identifying abdominal adiposity change obesity treatment?
Do multidisciplinary CKM pathways increase appropriate use of SGLT2 inhibitors, GLP-1-based therapies, renin-angiotensin system inhibitors or lipid-lowering treatment in patients who meet evidence-based criteria?
And do those changes ultimately improve outcomes?
Those are the questions that determine whether CKM becomes a genuine care model or another well-designed framework living mostly in guidelines and conference slides.
Digital infrastructure will almost certainly matter.
The ideal implementation probably does not depend on a primary-care clinician remembering to open a separate website, manually enter variables, calculate PREVENT risk and then consult another document to determine the CKM stage.
The electronic health record already contains much of the necessary information.
Blood pressure, BMI, laboratory values, diagnoses, medications and kidney function are frequently structured data.
A better system could calculate appropriate risk automatically, flag missing information such as urine albumin or waist circumference and present the clinician with a CKM stage together with evidence-based actions.
But automation brings its own governance questions.
Risk scores need to be transparent. Missing or outdated data can generate misleading classifications. Alerts can become background noise if clinicians receive too many. Automated recommendations still require context and shared decision-making.
The solution to fragmented care cannot simply be another pop-up window.
What the survey exposes is ultimately a broader problem in health policy.
Scientific medicine is becoming increasingly integrated while healthcare delivery remains organised around diseases, departments and reimbursement silos.
The biological argument behind CKM syndrome is already strong enough to have produced a major multisociety guideline.
The operational argument is only beginning.
The next phase of CKM policy therefore has less to do with convincing clinicians that the heart, kidneys and metabolic system interact.
Most already know they do.
It is about designing care as though that knowledge were true.
That means measuring the right things, calculating risk when it changes decisions, defining who coordinates care and ensuring that identification leads to access to effective treatment.
The preliminary survey suggests that the first step is already happening in many clinics.
Risk factors are being found.
The harder step is connecting them.
Cardiometabolic medicine has built the framework for whole-person risk. The implementation challenge is making sure patients encounter that framework in real care, rather than only in the guideline that describes it.

